Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Current Leases (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Current Leases for 3 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 45.83% to $2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Dec 2025, up 45.83% year-over-year, with the annual reading at $2.3 million for FY2025, 45.83% up from the prior year.
  • Current Leases for Q4 2025 was $2.3 million at Inhibrx Biosciences, up from $2.2 million in the prior quarter.
  • The five-year high for Current Leases was $2.3 million in Q4 2025, with the low at $1.6 million in Q4 2024.
  • Average Current Leases over 3 years is $2.0 million, with a median of $2.1 million recorded in 2023.
  • The sharpest move saw Current Leases dropped 22.69% in 2024, then soared 45.83% in 2025.
  • Over 3 years, Current Leases stood at $2.1 million in 2023, then decreased by 22.69% to $1.6 million in 2024, then soared by 45.83% to $2.3 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $2.3 million, $2.2 million, and $2.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.